NCT01121133View on ClinicalTrials.gov

A Study to Assess the Effect of Rifampin on the Metabolism of Navitoclax

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 31, 2010

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Lymphoma, Including Chronic Lymphocytic LeukemiaSolid Tumors
Interventions
DRUG

navitoclax

Subjects will be dosed with Navitoclax, then dosed with Navitoclax in combination with Rifampin.

DRUG

Rifampin

Subjects will be dosed with Navitoclax, then, dosed with Navitoclax in combination with Rifampin.

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY